Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21(12):729–49. https://doi.org/10.1038/s41580-020-00294-x.
Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 1984;259(5):3308–17.
Holt GD, Snow CM, Senior A, Haltiwanger RS, Gerace L, Hart GW. Nuclear pore complex glycoproteins contain cytoplasmically disposed O-linked N-acetylglucosamine. J Cell Biol. 1987;104(5):1157–64. https://doi.org/10.1083/jcb.104.5.1157.
Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Sci (New York NY). 2001;291(5512):2376–8. https://doi.org/10.1126/science.1058714.
Drougat L, Olivier-Van Stichelen S, Mortuaire M, Foulquier F, Lacoste AS, Michalski JC, Lefebvre T, Vercoutter-Edouart AS. Characterization of O-GlcNAc cycling and proteomic identification of differentially O-GlcNAcylated proteins during G1/S transition. Biochim Biophys Acta. 2012;1820(12):1839–48. https://doi.org/10.1016/j.bbagen.2012.08.024.
Liu AR, Ramakrishnan P. Regulation of Nuclear factor-kappab function by O-GlcNAcylation in inflammation and Cancer. Front cell Dev Biology. 2021;9:751761. https://doi.org/10.3389/fcell.2021.751761.
Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, Vocadlo DJ, Seagroves TN, Reginato MJ. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell. 2014;54(5):820–31. https://doi.org/10.1016/j.molcel.2014.04.026.
Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266(8):4706–12.
Akella NM, Ciraku L, Reginato MJ. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biol. 2019;17(1):52. https://doi.org/10.1186/s12915-019-0671-3.
Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446(7139):1017–22. https://doi.org/10.1038/nature05815.
Nolte D, Müller U. Human O-GlcNAc transferase (OGT): genomic structure, analysis of splice variants, fine mapping in Xq13.1. Mammalian genome. Official J Int Mammalian Genome Soc. 2002;13(1):62–4. https://doi.org/10.1007/s00335-001-2108-9.
Lazarus MB, Nam Y, Jiang J, Sliz P, Walker S. Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature. 2011;469(7331):564–7. https://doi.org/10.1038/nature09638.
Lubas WA, Hanover JA. Functional expression of O-linked GlcNAc transferase. Domain structure and substrate specificity. J Biol Chem. 2000;275(15):10983–8. https://doi.org/10.1074/jbc.275.15.10983.
Lairson LL, Henrissat B, Davies GJ, Withers SG. Glycosyltransferases: structures, functions, and mechanisms. Annu Rev Biochem. 2008;77:521–55. https://doi.org/10.1146/annurev.biochem.76.061005.092322.
Zhang N, Jiang H, Zhang K, Zhu J, Wang Z, Long Y, He Y, Feng F, Liu W, Ye F, Qu W. OGT as potential novel target: structure, function and inhibitors. Chemico-Biol Interact. 2022;357:109886. https://doi.org/10.1016/j.cbi.2022.109886.
Lubas WA, Frank DW, Krause M, Hanover JA. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J Biol Chem. 1997;272(14):9316–24. https://doi.org/10.1074/jbc.272.14.9316.
Hanover JA, Yu S, Lubas WB, Shin SH, Ragano-Caracciola M, Kochran J, Love DC. Mitochondrial and nucleocytoplasmic isoforms of O-linked GlcNAc transferase encoded by a single mammalian gene. Arch Biochem Biophys. 2003;409(2):287–97. https://doi.org/10.1016/s0003-9861(02)00578-7.
Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem. 1997;272(14):9308–15. https://doi.org/10.1074/jbc.272.14.9308.
Love DC, Kochan J, Cathey RL, Shin SH, Hanover JA. Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase. J Cell Sci. 2003;116(Pt 4):647–54. https://doi.org/10.1242/jcs.00246.
Liu L, Li L, Ma C, Shi Y, Liu C, Xiao Z, Zhang Y, Tian F, Gao Y, Zhang J, Ying W, Wang PG, Zhang L. O-GlcNAcylation of Thr(12)/Ser(56) in short-form O-GlcNAc transferase (sOGT) regulates its substrate selectivity. J Biol Chem. 2019;294(45):16620–33. https://doi.org/10.1074/jbc.RA119.009085.
Allan RK, Ratajczak T. Versatile TPR domains accommodate different modes of target protein recognition and function. Cell Stress Chaperones. 2011;16(4):353–67. https://doi.org/10.1007/s12192-010-0248-0.
Joiner CM, Levine ZG, Aonbangkhen C, Woo CM, Walker S. Aspartate residues far from the active site drive O-GlcNAc transferase substrate selection. J Am Chem Soc. 2019;141(33):12974–8. https://doi.org/10.1021/jacs.9b06061.
Jínek M, Rehwinkel J, Lazarus BD, Izaurralde E, Hanover JA, Conti E. The superhelical TPR-repeat domain of O-linked GlcNAc transferase exhibits structural similarities to importin alpha. Nat Struct Mol Biol. 2004;11(10):1001–7. https://doi.org/10.1038/nsmb833.
Blatch GL, Lässle M. The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. BioEssays: News Reviews Mol Cell Dev Biology. 1999;21(11):932–9. https://doi.org/10.1002/(SICI)1521-1878(199911)21:11%3C932::AID-BIES5%3E3.0.CO;2-N.
Wang Y, Shu H, Liu J, Jin X, Wang L, Qu Y, Xia M, Peng P, Feng Y, Wei M. EGF promotes PKM2 O-GlcNAcylation by stimulating O-GlcNAc transferase phosphorylation at Y976 and their subsequent association. J Biol Chem. 2022;298(9):102340. https://doi.org/10.1016/j.jbc.2022.102340.
Ding X, Jiang W, Zhou P, Liu L, Wan X, Yuan X, Wang X, Chen M, Chen J, Yang J, Kong C, Li B, Peng C, Wong CC, Hou F, Zhang Y. Mixed lineage leukemia 5 (MLL5) Protein Stability is cooperatively regulated by O-GlcNac Transferase (OGT) and Ubiquitin specific protease 7 (USP7). PLoS ONE. 2015;10(12):e0145023. https://doi.org/10.1371/journal.pone.0145023.
Zhai L, Yang X, Dong J, Qian L, Gao Y, Lv Y, Chen L, Chen B, Zhou F. O–GlcNAcylation mediates endometrial cancer progression by regulating the Hippo–YAP pathway. Int J Oncol. 2023;63(2). https://doi.org/10.3892/ijo.2023.5538.
Wang Y, Wang G, Liu Y, Yang F, Zhang H, Kong Y. Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2023;120:155062. https://doi.org/10.1016/j.phymed.2023.155062.
Poulose N, Forsythe N, Polonski A, Gregg G, Maguire S, Fuchs M, Minner S, Sauter G, McDade SS, Mills IG. VPRBP functions downstream of the androgen receptor and OGT to restrict p53 activation in prostate Cancer. Mol cancer Research: MCR. 2022;20(7):1047–60. https://doi.org/10.1158/1541-7786.Mcr-21-0477.
Shen H, Zhao X, Chen J, Qu W, Huang X, Wang M, Shao Z, Shu Q, Li X. O-GlcNAc transferase ogt regulates embryonic neuronal development through modulating Wnt/β-catenin signaling. Hum Mol Genet. 2021;31(1):57–68. https://doi.org/10.1093/hmg/ddab223.
Levine ZG, Potter SC, Joiner CM, Fei GQ, Nabet B, Sonnett M, Zachara NE, Gray NS, Paulo JA, Walker S. Mammalian cell proliferation requires noncatalytic functions of O-GlcNAc transferase. Proc Natl Acad Sci USA. 2021;118(4). https://doi.org/10.1073/pnas.2016778118.
Li X, Yue X, Sepulveda H, Burt RA, Scott DA, S, AC SAM, Rao A. OGT controls mammalian cell viability by regulating the proteasome/mTOR/ mitochondrial axis. Proc Natl Acad Sci USA. 2023;120(3):e2218332120. https://doi.org/10.1073/pnas.2218332120.
Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain. 2009;132(Pt 7):1820–32. https://doi.org/10.1093/brain/awp099.
Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu X, Zhu G, Zhao Y, Chen Y, Yu Y, Pan Q, Wang J, Sun F. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun. 2017;8:15280. https://doi.org/10.1038/ncomms15280.
Jiang M, Qiu Z, Zhang S, Fan X, Cai X, Xu B, Li X, Zhou J, Zhang X, Chu Y, Wang W, Liang J, Horvath T, Yang X, Wu K, Nie Y, Fan D. Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling. Oncotarget. 2016;7(38):61390–402. https://doi.org/10.18632/oncotarget.11359.
Zhu G, Qian M, Lu L, Chen Y, Zhang X, Wu Q, Liu Y, Bian Z, Yang Y, Guo S, Wang J, Pan Q, Sun F. O-GlcNAcylation of YY1 stimulates tumorigenesis in colorectal cancer cells by targeting SLC22A15 and AANAT. Carcinogenesis. 2019;40(9):1121–31. https://doi.org/10.1093/carcin/bgz010.
Shi R, Tao J, Jiang X, Li M, Zhu R, Luo S, Lu Z. Fructose-1,6-bisphosphatase 1 suppresses PPARα-mediated gene transcription and non-small-cell lung cancer progression. Am J cancer Res. 2023;13(10):4742–54.
Wang Z, Li M, Jiang H, Luo S, Shao F, Xia Y, Yang M, Ren X, Liu T, Yan M, Qian X, He H, Guo D, Duan Y, Wu K, Wang L, Ji G, Shen Y, Li L, Zheng P, Dong B, Fang J, Zheng M, Liang T, Li H, Yu R, Xu D, Lu Z. Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth. Nat Cell Biol. 2022;24(11):1655–65. https://doi.org/10.1038/s41556-022-01009-4.
Yin Q, Zheng M, Luo Q, Jiang D, Zhang H, Chen C. YB-1 as an oncoprotein: functions, Regulation, post-translational modifications, and targeted therapy. Cells. 2022;11(7). https://doi.org/10.3390/cells11071217.
Tao Z, Ruan H, Sun L, Kuang D, Song Y, Wang Q, Wang T, Hao Y, Chen K. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Cancer Immunol Res. 2019;7(7):1135–47. https://doi.org/10.1158/2326-6066.Cir-18-0648.
Liu Q, Tao T, Liu F, Ni R, Lu C, Shen A. Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma. Exp Cell Res. 2016;349(2):230–8. https://doi.org/10.1016/j.yexcr.2016.10.011.
Zhou P, Chang WY, Gong DA, Xia J, Chen W, Huang LY, Liu R, Liu Y, Chen C, Wang K, Tang N, Huang AL. High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate. Cell Metabol. 2023;35(11):1961–75. .e6.
Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Sem Cancer Biol. 2022;85:123–54. https://doi.org/10.1016/j.semcancer.2021.05.010.
Xu Y, Sheng X, Zhao T, Zhang L, Ruan Y, Lu H. O-GlcNAcylation of MEK2 promotes the proliferation and migration of breast cancer cells. Glycobiology. 2021;31(5):571–81. https://doi.org/10.1093/glycob/cwaa103.
Chai Y, Du Y, Zhang S, Xiao J, Luo Z, He F, Huang K. MicroRNA-485-5p reduces O-GlcNAcylation of Bmi-1 and inhibits colorectal cancer proliferation. Exp Cell Res. 2018;368(1):111–8. https://doi.org/10.1016/j.yexcr.2018.04.020.
Li J, Ahmad M, Sang L, Zhan Y, Wang Y, Yan Y, Liu Y, Mi W, Lu M, Dai Y, Zhang R, Dong MQ, Yang YG, Wang X, Sun J, Li J. O-GlcNAcylation promotes the cytosolic localization of the m(6)a reader YTHDF1 and colorectal cancer tumorigenesis. J Biol Chem. 2023;299(6):104738. https://doi.org/10.1016/j.jbc.2023.104738.
Su Z, Gao A, Li X, Zou S, He C, Wu J, Ding WQ, Zhou J. DNA polymerase Iota promotes esophageal squamous cell Carcinoma Proliferation through Erk-OGT-Induced G6PD overactivation. Front Oncol. 2021;11:706337. https://doi.org/10.3389/fonc.2021.706337.
Yu FY, Zhou CY, Liu YB, Wang B, Mao L, Li Y. miR-483 is down-regulated in gastric cancer and suppresses cell proliferation, invasion and protein O-GlcNAcylation by targeting OGT. Neoplasma. 2018;65(3):406–14. https://doi.org/10.4149/neo_2018_170608N411.
Ning D, Chen J, Du P, Liu Q, Cheng Q, Li X, Zhang B, Chen X, Jiang L. The crosstalk network of XIST/miR-424-5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer. Liver International: Official J Int Association Study Liver. 2021;41(8):1933–44. https://doi.org/10.1111/liv.14904.
Zheng W, Li H, Zhang H, Zhang C, Zhu Z, Liang H, Zhou Y. Long noncoding RNA RHPN1-AS1 promotes colorectal cancer progression via targeting miR-7-5p/OGT axis. Cancer Cell Int. 2020;20:54. https://doi.org/10.1186/s12935-020-1110-9.
Gerstberger S, Jiang Q, Ganesh K, Metastasis. Cell. 2023;186(8):1564–79. https://doi.org/10.1016/j.cell.2023.03.003.
Mittal V. Epithelial mesenchymal transition in Tumor Metastasis. Annu Rev Pathol. 2018;13:395–412. https://doi.org/10.1146/annurev-pathol-020117-043854.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. https://doi.org/10.1038/s41580-018-0080-4.
Jiang M, Xu B, Li X, Shang Y, Chu Y, Wang W, Chen D, Wu N, Hu S, Zhang S, Li M, Wu K, Yang X, Liang J, Nie Y, Fan D. O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit. Oncogene. 2019;38(3):301–16. https://doi.org/10.1038/s41388-018-0435-5.
Ge X, Peng X, Li M, Ji F, Chen J, Zhang D. OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells. Pathol Res Pract. 2021;225:153580. https://doi.org/10.1016/j.prp.2021.153580.
Jin FZ, Yu C, Zhao DZ, Wu MJ, Yang Z. A correlation between altered O-GlcNAcylation, migration and with changes in E-cadherin levels in ovarian cancer cells. Exp Cell Res. 2013;319(10):1482–90. https://doi.org/10.1016/j.yexcr.2013.03.013.
de Almeida LGN, Thode H, Eslambolchi Y, Chopra S, Young D, Gill S, Devel L, Dufour A. Matrix metalloproteinases: from Molecular mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacol Rev. 2022;74(3):712–68. https://doi.org/10.1124/pharmrev.121.000349.
Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M, Prusa R, Kizek R. Matrix metalloproteinases. Curr Med Chem. 2010;17(31):3751–68. https://doi.org/10.2174/092986710793213724.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. https://doi.org/10.1016/j.cell.2010.03.015.
Qiao Z, Dang C, Zhou B, Li S, Zhang W, Jiang J, Zhang J, Ma Y, Kong R, Ma Z. Downregulation of O-linked N-acetylglucosamine transferase by RNA interference decreases MMP9 expression in human esophageal cancer cells. Oncol Lett. 2016;11(5):3317–23. https://doi.org/10.3892/ol.2016.4428.
Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 2012;287(14):11070–81. https://doi.org/10.1074/jbc.M111.302547.
Li X, Wu Z, He J, Jin Y, Chu C, Cao Y, Gu F, Wang H, Hou C, Liu X, Zou Q. OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP. Oncogene. 2021;40(30):4859–71. https://doi.org/10.1038/s41388-021-01901-7.
Lv Z, Ma G, Zhong Z, Xie X, Li B, Long D. O-GlcNAcylation of RAB10 promotes hepatocellular carcinoma progression. Carcinogenesis. 2023;44(10–11):785–94. https://doi.org/10.1093/carcin/bgad034.
Hao JW, Wang J, Guo H, Zhao YY, Sun HH, Li YF, Lai XY, Zhao N, Wang X, Xie C, Hong L, Huang X, Wang HR, Li CB, Liang B, Chen S, Zhao TJ. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. 2020;11(1):4765. https://doi.org/10.1038/s41467-020-18565-8.
Son NH, Basu D, Samovski D, Pietka TA, Peche VS, Willecke F, Fang X, Yu SQ, Scerbo D, Chang HR, Sun F, Bagdasarov S, Drosatos K, Yeh ST, Mullick AE, Shoghi KI, Gumaste N, Kim K, Huggins LA, Lhakhang T, Abumrad NA, Goldberg IJ. Endothelial cell CD36 optimizes tissue fatty acid uptake. J Clin Investig. 2018;128(10):4329–42. https://doi.org/10.1172/jci99315.
Jiang M, Wu N, Xu B, Chu Y, Li X, Su S, Chen D, Li W, Shi Y, Gao X, Zhang H, Zhang Z, Du W, Nie Y, Liang J, Fan D. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics. 2019;9(18):5359–73. https://doi.org/10.7150/thno.34024.
Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, Ren B, Pan T, He C. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–20. https://doi.org/10.1038/nature12730.
Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m(6)a modification. Trends Genet. 2020;36(3):177–88. https://doi.org/10.1016/j.tig.2019.12.007.
Yang Y, Yan Y, Yin J, Tang N, Wang K, Huang L, Hu J, Feng Z, Gao Q, Huang A. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner. Signal Transduct Target Therapy. 2023;8(1):63. https://doi.org/10.1038/s41392-023-01316-8.
Wang G, Xu Z, Sun J, Liu B, Ruan Y, Gu J, Song S. O-GlcNAcylation enhances Reticulon 2 protein stability and its promotive effects on gastric cancer progression. Cell Signal. 2023;108:110718. https://doi.org/10.1016/j.cellsig.2023.110718.
Lin CH, Liao CC, Wang SY, Peng CY, Yeh YC, Chen MY, Chou TY. Comparative O-GlcNAc proteomic analysis reveals a role of O-GlcNAcylated SAM68 in Lung Cancer aggressiveness. Cancers. 2022;14(1). https://doi.org/10.3390/cancers14010243.
Liu HY, Liu YY, Yang F, Zhang L, Zhang FL, Hu X, Shao ZM, Li DQ. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res. 2020;48(7):3638–56. https://doi.org/10.1093/nar/gkaa130.
Zhang FL, Yang SY, Liao L, Zhang TM, Zhang YL, Hu SY, Deng L, Huang MY, Andriani L, Ma XY, Shao ZM, Li DQ. Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer. Theranostics. 2023;13(3):973–90. https://doi.org/10.7150/thno.79688.
Liu YY, Liu HY, Yu TJ, Lu Q, Zhang FL, Liu GY, Shao ZM, Li DQ. O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression. Cell Death Differ. 2022;29(4):861–73. https://doi.org/10.1038/s41418-021-00901-0.
Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, Vosseller K, Reginato MJ. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene. 2010;29(19):2831–42. https://doi.org/10.1038/onc.2010.41.
Liu Y, Huang H, Cao Y, Wu Q, Li W, Zhang J. Suppression of OGT by microRNA24 reduces FOXA1 stability and prevents breast cancer cells invasion. Biochem Biophys Res Commun. 2017;487(3):755–62. https://doi.org/10.1016/j.bbrc.2017.04.135.
Tao T, He Z, Shao Z, Lu H. Table 3 O-GlcNAcylation promotes metastasis of triple negative breast cancer. Oncotarget. 2016;7(16):22807–18. https://doi.org/10.18632/oncotarget.8182.
Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, Sethi G, Tergaonkar V. NF-κB as a regulator of cancer metastasis and therapy response: a focus on epithelial-mesenchymal transition. J Cell Physiol. 2022;237(7):2770–95. https://doi.org/10.1002/jcp.30759.
Mortezaee K, Najafi M, Farhood B, Ahmadi A, Shabeeb D, Musa AE. NF-κB targeting for overcoming tumor resistance and normal tissues toxicity. J Cell Physiol. 2019;234(10):17187–204. https://doi.org/10.1002/jcp.28504.
Ali A, Kim SH, Kim MJ, Choi MY, Kang SS, Cho GJ, Kim YS, Choi JY, Choi WS. O-GlcNAcylation of NF-κB promotes Lung Metastasis of Cervical Cancer cells via Upregulation of CXCR4 expression. Mol Cells. 2017;40(7):476–84. https://doi.org/10.14348/molcells.2017.2309.
Niu Y, Xia Y, Wang J, Shi X. O-GlcNAcylation promotes migration and invasion in human ovarian cancer cells via the RhoA/ROCK/MLC pathway. Mol Med Rep. 2017;15(4):2083–9. https://doi.org/10.3892/mmr.2017.6244.
Seo HG, Kim HB, Yoon JY, Kweon TH, Park YS, Kang J, Jung J, Son S, Yi EC, Lee TH, Yang WH, Cho JW. Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion. Cell Death Dis. 2020;11(9):815. https://doi.org/10.1038/s41419-020-02999-5.
Wu N, Jiang M, Han Y, Liu H, Chu Y, Liu H, Cao J, Hou Q, Zhao Y, Xu B, Xie X. O-GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5. J Cell Mol Med. 2019;23(2):1354–62. https://doi.org/10.1111/jcmm.14038.
Huang X, Pan Q, Sun D, Chen W, Shen A, Huang M, Ding J, Geng M. O-GlcNAcylation of cofilin promotes breast cancer cell invasion. J Biol Chem. 2013;288(51):36418–25. https://doi.org/10.1074/jbc.M113.495713.
Wang L, Li G, Zhou Z, Ge C, Chen Q, Liu Y, Zhang N, Zhang K, Niu M, Li W, Zhong X, Wu S, Zhang J, Liu Y. Chromatin-associated OGT promotes the malignant progression of hepatocellular carcinoma by activating ZNF263. Oncogene. 2023;42(30):2329–46. https://doi.org/10.1038/s41388-023-02751-1.
Zhu G, Tao T, Zhang D, Liu X, Qiu H, Han L, Xu Z, Xiao Y, Cheng C, Shen A. O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression. Glycobiology. 2016;26(8):820–33. https://doi.org/10.1093/glycob/cww025.
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discovery. 2022;21(2):141–62. https://doi.org/10.1038/s41573-021-00339-6.
Yu T, Wang Y, Fan Y, Fang N, Wang T, Xu T, Shu Y. CircRNAs in cancer metabolism: a review. J Hematol Oncol. 2019;12(1):90. https://doi.org/10.1186/s13045-019-0776-8.
Mikawa T, ME LL, Takaori-Kondo A, Inagaki N, Yokode M, Kondoh H. Dysregulated glycolysis as an oncogenic event. Cell Mol Life Sci. 2015;72(10):1881–92. https://doi.org/10.1007/s00018-015-1840-3.
Hu H, Zhu W, Qin J, Chen M, Gong L, Li L, Liu X, Tao Y, Yin H, Zhou H, Zhou L, Ye D, Ye Q, Gao D. Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology (Baltimore MD). 2017;65(2):515–28. https://doi.org/10.1002/hep.28887.
He Y, Wang X, Lu W, Zhang D, Huang L, Luo Y, Xiong L, Li H, Zhang P, Li Q, Liang S. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell Death Dis. 2022;13(2):118. https://doi.org/10.1038/s41419-022-04576-4.
Liang J, Liu C, Xu D, Xie K, Li A. LncRNA NEAT1 facilitates glioma progression via stabilizing PGK1. J Translational Med. 2022;20(1):80. https://doi.org/10.1186/s12967-022-03273-2.
Nie H, Ju H, Fan J, Shi X, Cheng Y, Cang X, Zheng Z, Duan X, Yi W. O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth. Nat Commun. 2020;11(1):36. https://doi.org/10.1038/s41467-019-13601-8.
Singh JP, Qian K, Lee JS, Zhou J, Han X, Zhang B, Ong Q, Ni W, Jiang M, Ruan HB, Li MD, Zhang K, Ding Z, Lee P, Singh K, Wu J, Herzog RI, Kaech S, Wendel HG, Yates JR 3rd, Han W, Sherwin RS, Nie Y, Yang X. O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth. Oncogene. 2020;39(3):560–73. https://doi.org/10.1038/s41388-019-0975-3.
He X, Wu N, Li R, Zhang H, Zhao Y, Nie Y, Wu J. IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression. Cell Oncol (Dordrecht). 2023;46(1):145–64. https://doi.org/10.1007/s13402-022-00740-2.
Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1). https://doi.org/10.1084/jem.20201606.
Bacci M, Lorito N, Smiriglia A, Morandi A. Fat and Furious: lipid metabolism in Antitumoral Therapy Response and Resistance. Trends cancer. 2021;7(3):198–213. https://doi.org/10.1016/j.trecan.2020.10.004.
Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Design. 2014;20(15):2619–26. https://doi.org/10.2174/13816128113199990486.
Sodi VL, Bacigalupa ZA, Ferrer CM, Lee JV, Gocal WA, Mukhopadhyay D, Wellen KE, Ivan M, Reginato MJ. Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation. Oncogene. 2018;37(7):924–34. https://doi.org/10.1038/onc.2017.395.
Schug ZT, Vande Voorde J, Gottlieb E. The metabolic fate of acetate in cancer. Nat Rev Cancer. 2016;16(11):708–17. https://doi.org/10.1038/nrc.2016.87.
Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, Huang Z, Barnett S, Mickey BE, DeBerardinis RJ, Tu BP, Maher EA, Bachoo RM. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603–14. https://doi.org/10.1016/j.cell.2014.11.025.
Ciraku L, Bacigalupa ZA, Ju J, Moeller RA, Le Minh G, Lee RH, Smith MD, Ferrer CM, Trefely S, Izzo LT, Doan MT, Gocal WA, D’Agostino L, Shi W, Jackson JG, Katsetos CD, Wellen KE, Snyder NW, Reginato MJ. O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation. Oncogene. 2022;41(14):2122–36. https://doi.org/10.1038/s41388-022-02237-6.
Su KJ, Yu YL. Downregulation of SHIP2 by Hepatitis B Virus X promotes the Metastasis and Chemoresistance of Hepatocellular Carcinoma through SKP2. Cancers. 2019;11(8). https://doi.org/10.3390/cancers11081065.
Zhang H, Wang Q, Liu J, Cao H. Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma. Oncol Lett. 2018;15(6):9377–84. https://doi.org/10.3892/ol.2018.8536.
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Reviews Disease Primers. 2016;2:16061. https://doi.org/10.1038/nrdp.2016.61.
Qian L, Yang X, Li S, Zhao H, Gao Y, Zhao S, Lv X, Zhang X, Li L, Zhai L, Zhou F, Chen B. Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer. Cell Death Discovery. 2021;7(1):112. https://doi.org/10.1038/s41420-021-00489-x.
Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R, Lv X, Li J, Chen B. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics. 2018;8(19):5200–12. https://doi.org/10.7150/thno.27806.
Huang W, Chen L, Zhu K, Wang D. Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin. Cell Death Discovery. 2021;7(1):379. https://doi.org/10.1038/s41420-021-00715-6.
Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447. https://doi.org/10.1016/j.pharmthera.2019.107447.
Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8. https://doi.org/10.1038/nrc1074.
Very N, Hardivillé S, Decourcelle A, Thévenet J, Djouina M, Page A, Vergoten G, Schulz C, Kerr-Conte J, Lefebvre T, Dehennaut V. El Yazidi-Belkoura I. Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer. Oncogene. 2022;41(5):745–56. https://doi.org/10.1038/s41388-021-02121-9.
Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol. 2020;60:457–76. https://doi.org/10.1146/annurev-pharmtox-010919-023603.
Sekine H, Okazaki K, Kato K, Alam MM, Shima H, Katsuoka F, Tsujita T, Suzuki N, Kobayashi A, Igarashi K, Yamamoto M, Motohashi H. O-GlcNAcylation Signal mediates proteasome inhibitor resistance in Cancer cells by stabilizing NRF1. Mol Cell Biol. 2018;38(17). https://doi.org/10.1128/mcb.00252-18.
Shoaib Z, Fan TM, Irudayaraj JMK. Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2022;179(2):201–17. https://doi.org/10.1111/bph.15713.
Hattinger CM, Tavanti E, Fanelli M, Vella S, Picci P, Serra M. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Expert Opin Drug Metab Toxicol. 2017;13(3):245–57. https://doi.org/10.1080/17425255.2017.1246532.
Sun MX, An HY, Sun YB, Sun YB, Bai B. LncRNA EBLN3P attributes methotrexate resistance in osteosarcoma cells through miR-200a-3p/O-GlcNAc transferase pathway. J Orthop Surg Res. 2022;17(1):557. https://doi.org/10.1186/s13018-022-03449-y.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D’Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. Prostate Cancer, Version 4.2023, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. 2023;21(10):1067–96. https://doi.org/10.6004/jnccn.2023.0050.
Xia M, Wang S, Qi Y, Long K, Li E, He L, Pan F, Guo Z, Hu Z. Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel. Front Oncol. 2022;12:993243. https://doi.org/10.3389/fonc.2022.993243.
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet (London England). 2016;388(10061):2796–810. https://doi.org/10.1016/s0140-6736(16)30512-8.
Wang L, Chen S, Zhang Z, Zhang J, Mao S, Zheng J, Xuan Y, Liu M, Cai K, Zhang W, Guo Y, Zhai W, Yao X. Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer. BMC Cancer. 2018;18(1):1141. https://doi.org/10.1186/s12885-018-5033-y.
Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009;115(12):2652–9. https://doi.org/10.1002/cncr.24313.
Lee HW, Kang MJ, Kwon YJ, Abdi Nansa S, Jung EH, Kim SH, Lee SJ, Jeong KC, Kim Y, Cheong H, Seo HK. Targeted inhibition of O-Linked β-N-Acetylglucosamine transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor traits in Chemoresistant Urothelial Carcinoma of the bladder. Biomedicines. 2022;10(5). https://doi.org/10.3390/biomedicines10051162.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57. https://doi.org/10.1038/bjc.1972.33.
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. https://doi.org/10.1080/01926230701320337.
Corcoran GB, Fix L, Jones DP, Moslen MT, Nicotera P, Oberhammer FA, Buttyan R. Apoptosis: molecular control point in toxicity. Toxicol Appl Pharmcol. 1994;128(2):169–81. https://doi.org/10.1006/taap.1994.1195.
Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol. 1997;6(3):133–42. https://doi.org/10.1016/s0960-7404(97)00015-7.
Evan GI, Brown L, Whyte M, Harrington E. Apoptosis and the cell cycle. Curr Opin Cell Biol. 1995;7(6):825–34. https://doi.org/10.1016/0955-0674(95)80066-2.
Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Experimental Clin cancer Research: CR. 2011;30(1):87. https://doi.org/10.1186/1756-9966-30-87.
Zhou P, Chang WY, Gong DA, Huang LY, Liu R, Liu Y, Xia J, Wang K, Tang N, Huang AL. O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma. Oncogene. 2023;42(10):725–36. https://doi.org/10.1038/s41388-022-02589-z.
Yu M, Chu S, Fei B, Fang X, Liu Z. O-GlcNAcylation of ITGA5 facilitates the occurrence and development of colorectal cancer. Exp Cell Res. 2019;382(2):111464. https://doi.org/10.1016/j.yexcr.2019.06.009.
Li Y, Wang L, Liu J, Zhang P, An M, Han C, Li Y, Guan X, Zhang K. O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer. Oncogene. 2017;36(45):6293–305. https://doi.org/10.1038/onc.2017.223.
Gao S, Yin H, Tong H, Zhan K, Yang G, Hossain MA, Li T, Gou X, He W. Nucleolar and Spindle Associated Protein 1 (NUSAP1) promotes bladder Cancer Progression through the TGF-β signaling pathway. OncoTargets Therapy. 2020;13:813–25. https://doi.org/10.2147/ott.S237127.
Hou J, Lu Z, Liu X, Luo B, Qu G, Xu Y, Tang C. Increased NUSAP1 expression is associated with lymph node metastasis and survival prognosis in bladder urothelial carcinoma. Sci Rep. 2022;12(1):7003. https://doi.org/10.1038/s41598-022-11137-4.
Chen Y, Liu J, Zhang W, Kadier A, Wang R, Zhang H, Yao X. O-GlcNAcylation enhances NUSAP1 Stability and promotes bladder Cancer aggressiveness. OncoTargets Therapy. 2021;14:445–54. https://doi.org/10.2147/ott.S258175.
Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781. https://doi.org/10.1016/j.lfs.2019.116781.
Kharkar PS. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012–2015). Expert Opin Ther Pat. 2017;27(7):753–61. https://doi.org/10.1080/13543776.2017.1325465.
Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Research: Official J Japan Soc Hepatol. 2013;43(2):147–54. https://doi.org/10.1111/j.1872-034X.2012.01113.x.
Yuan J, Lv T, Yang J, Wu Z, Yan L, Yang J, Shi Y, Jiang L. HDLBP promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by suppressing Trim71-dependent RAF1 degradation. Cell Mol Gastroenterol Hepatol. 2023;15(2):307–25. https://doi.org/10.1016/j.jcmgh.2022.10.005.
Cao B, Duan M, Xing Y, Liu C, Yang F, Li Y, Yang T, Wei Y, Gao Q, Jiang J. O-GlcNAc transferase activates stem-like cell potential in hepatocarcinoma through O-GlcNAcylation of eukaryotic initiation factor 4E. J Cell Mol Med. 2019;23(4):2384–98. https://doi.org/10.1111/jcmm.14043.
Le Minh G, Esquea EM, Dhameliya TT, Merzy J, Lee MH, Ball LE, Reginato MJ. Kruppel-like factor 8 regulates triple negative breast cancer stem cell-like activity. Front Oncol. 2023;13:1141834. https://doi.org/10.3389/fonc.2023.1141834.
Liang C, Zhang X, Yang M, Dong X. Recent progress in Ferroptosis Inducers for Cancer Therapy. Advanced materials (Deerfield Beach. Fla). 2019;31(51):e1904197. https://doi.org/10.1002/adma.201904197.
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82. https://doi.org/10.1038/s41580-020-00324-8.
Wu X, Li Y, Zhang S, Zhou X. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11(7):3052–9. https://doi.org/10.7150/thno.54113.
Latunde-Dada GO, Ferroptosis. Role of lipid peroxidation, iron and ferritinophagy. Biochimica et biophysica acta General subjects. 2017;1861(8):1893–900. https://doi.org/10.1016/j.bbagen.2017.05.019
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369–79. https://doi.org/10.1038/cdd.2015.158.
Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620. https://doi.org/10.1007/s13238-020-00789-5.
Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4. https://doi.org/10.1038/s41586-019-1170-y.
Tang J, Long G, Hu K, Xiao D, Liu S, Xiao L, Zhou L, Tao Y. Targeting USP8 inhibits O-GlcNAcylation of SLC7A11 to promote Ferroptosis of Hepatocellular Carcinoma via stabilization of OGT. Adv Sci (Weinheim Baden-Wurttemberg Germany). 2023;10(33):e2302953. https://doi.org/10.1002/advs.202302953.
Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR, Hypoxia. Hypoxia-inducible transcription factors, and Renal Cancer. Eur Urol. 2016;69(4):646–57. https://doi.org/10.1016/j.eururo.2015.08.007.
Yang Z, Wei X, Ji C, Ren X, Su W, Wang Y, Zhou J, Zhao Z, Zhou P, Zhao K, Yao B, Song N, Qin C. OGT/HIF-2α axis promotes the progression of clear cell renal cell carcinoma and regulates its sensitivity to ferroptosis. iScience. 2023;26(11):108148. https://doi.org/10.1016/j.isci.2023.108148.
Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3–12. https://doi.org/10.1002/path.2697.
Liu S, Yao S, Yang H, Liu S, Wang Y, Autophagy. Regulator of cell death. Cell Death Dis. 2023;14(10):648. https://doi.org/10.1038/s41419-023-06154-8.
Ganzleben I, Neurath MF, Becker C. Autophagy in Cancer Therapy-Molecular mechanisms and current clinical advances. Cancers. 2021;13(21). https://doi.org/10.3390/cancers13215575.
Jin L, Yuan F, Dai G, Yao Q, Xiang H, Wang L, Xue B, Shan Y, Liu X. Blockage of O-linked GlcNAcylation induces AMPK-dependent autophagy in bladder cancer cells. Cell Mol Biol Lett. 2020;25:17. https://doi.org/10.1186/s11658-020-00208-x.
Kostecki KL, Iida M, Crossman BE, Salgia R, Harari PM, Bruce JY, Wheeler DL. Immune escape strategies in Head and Neck Cancer: evade, resist, inhibit, Recruit. Cancers. 2024;16(2). https://doi.org/10.3390/cancers16020312.
Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018;18(1):556. https://doi.org/10.1186/s12885-018-4441-3.
Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 expression in Cancer. Mol Cell. 2019;76(3):359–70. https://doi.org/10.1016/j.molcel.2019.09.030.
Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy. Sem Cancer Biol. 2022;86(Pt 3):137–50. https://doi.org/10.1016/j.semcancer.2022.03.014.
Zhu Q, Wang H, Chai S, Xu L, Lin B, Yi W, Wu L. O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation. Proc Natl Acad Sci USA. 2023;120(13):e2216796120. https://doi.org/10.1073/pnas.2216796120.
Yuan Y, Wang L, Ge D, Tan L, Cao B, Fan H, Xue L. Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8(+) T cells. Cancer Lett. 2021;500:98–106. https://doi.org/10.1016/j.canlet.2020.12.012.
Ali A, Kim MJ, Kim MY, Lee HJ, Roh GS, Kim HJ, Cho GJ, Choi WS. Quercetin induces cell death in cervical cancer by reducing O-GlcNAcylation of adenosine monophosphate-activated protein kinase. Anat cell Biology. 2018;51(4):274–83. https://doi.org/10.5115/acb.2018.51.4.274.
Zhang C, Niu Y, Wang Z, Xu X, Li Y, Ma L, Wang J, Yu Y. Corosolic acid inhibits cancer progression by decreasing the level of CDK19-mediated O-GlcNAcylation in liver cancer cells. Cell Death Dis. 2021;12(10):889. https://doi.org/10.1038/s41419-021-04164-y.
Ortiz-Meoz RF, Jiang J, Lazarus MB, Orman M, Janetzko J, Fan C, Duveau DY, Tan ZW, Thomas CJ, Walker S. A small molecule that inhibits OGT activity in cells. ACS Chem Biol. 2015;10(6):1392–7. https://doi.org/10.1021/acschembio.5b00004.
Loi EM, Weiss M, Pajk S, Gobec M, Tomašič T, Pieters RJ, Anderluh M. Intracellular hydrolysis of small-molecule O-Linked N-Acetylglucosamine transferase inhibitors differs among cells and is not required for its inhibition. Molecules. 2020;25(15). https://doi.org/10.3390/molecules25153381.
Li M, Duan F, Pan Z, Liu X, Lu W, Liang C, Fang Z, Peng P, Jia D. Astragalus Polysaccharide promotes Doxorubicin-Induced apoptosis by reducing O-GlcNAcylation in Hepatocellular Carcinoma. Cells. 2023;12(6). https://doi.org/10.3390/cells12060866.
Yang R, Wang L, Wu Z, Yin Y, Jiang SW. How nanotechniques could vitalize the O-GlcNAcylation-Targeting Approach for Cancer Therapy. Int J Nanomed. 2022;17:1829–41. https://doi.org/10.2147/ijn.S360488.
Add Comment